Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin in nonalcoholic fatty liver disease
IRCT2017060212789N14Phase 3Completed
- Sponsor
- Vice Chancellor for Research of Kurdistan University of Medical Sciences
- Start
- Apr 2017
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of rosuvastatin in metabolic dysfunction-associated steatotic liver disease (MASLD), sponsored by Vice Chancellor for Research of Kurdistan University of Medical Sciences. Primary endpoints: Change in steatosis and Change in fibrosis. Started Apr 2017; status: completed.
02
Drugs
rosuvastatin
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on IRCT2017060212789N14.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT2017060212789N14.